Terms: = Ovarian cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
423 results:
1. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-pd-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
2. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
3. Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade.
Nie H; Saini P; Miyamoto T; Liao L; Zielinski RJ; Liu H; Zhou W; Wang C; Murphy B; Towers M; Yang T; Qi Y; Kannan T; Kossenkov A; Tateno H; Claiborne DT; Zhang N; Abdel-Mohsen M; Zhang R
Nat Commun; 2024 Apr; 15(1):2853. PubMed ID: 38565883
[TBL] [Abstract] [Full Text] [Related]
4. Associations of pd-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
5. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.
Kasikova L; Rakova J; Hensler M; Lanickova T; Tomankova J; Pasulka J; Drozenova J; Mojzisova K; Fialova A; Vosahlikova S; Laco J; Ryska A; Dundr P; Kocian R; Brtnicky T; Skapa P; Capkova L; Kovar M; Prochazka J; Praznovec I; Koblizek V; Taskova A; Tanaka H; Lischke R; Mendez FC; Vachtenheim J; Heinzelmann-Schwarz V; Jacob F; McNeish IA; Halaska MJ; Rob L; Cibula D; Orsulic S; Galluzzi L; Spisek R; Fucikova J
Nat Commun; 2024 Mar; 15(1):2528. PubMed ID: 38514660
[TBL] [Abstract] [Full Text] [Related]
6. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for ovarian cancer.
Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
[No Abstract] [Full Text] [Related]
7. Linear IgA bullous dermatosis associated with immunotherapy.
Momin B; Nguyen TF; Glade D; Messer A
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478666
[TBL] [Abstract] [Full Text] [Related]
8. Machine learning developed a CD8
Chen R; Zheng Y; Fei C; Ye J; Fei H
Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
[TBL] [Abstract] [Full Text] [Related]
9. New windows of surgical opportunity for gynecological cancers in the era of targeted therapies.
Peters I; Marchetti C; Scambia G; Fagotti A
Int J Gynecol Cancer; 2024 Mar; 34(3):352-362. PubMed ID: 38438181
[TBL] [Abstract] [Full Text] [Related]
10. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract] [Full Text] [Related]
11. Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3.
Schadeck J; Oberg HH; Peipp M; Hedemann N; Schamel WW; Bauerschlag D; Wesch D
Front Immunol; 2023; 14():1286097. PubMed ID: 38259448
[TBL] [Abstract] [Full Text] [Related]
12. Metabolic-Related Gene Prognostic Index for Predicting Prognosis, Immunotherapy Response, and Candidate Drugs in ovarian cancer.
Guo S; Liu Y; Sun Y; Zhou H; Gao Y; Wang P; Zhi H; Zhang Y; Gan J; Ning S
J Chem Inf Model; 2024 Feb; 64(3):1066-1080. PubMed ID: 38238993
[TBL] [Abstract] [Full Text] [Related]
13. A Microfluidics Approach for ovarian cancer Immune Monitoring in an Outpatient Setting.
Libbrecht S; Vankerckhoven A; de Wijs K; Baert T; Thirion G; Vandenbrande K; Van Gorp T; Timmerman D; Coosemans A; Lagae L
Cells; 2023 Dec; 13(1):. PubMed ID: 38201211
[TBL] [Abstract] [Full Text] [Related]
14. Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment.
Wu CJ; Pan KF; Chen JQ; Tao Y-; Liu YC; Chen BR; Hsu C; Wang MY; Sheu BC; Hsiao M; Hua KT; Wei LH
Oncogene; 2024 Feb; 43(7):511-523. PubMed ID: 38177412
[TBL] [Abstract] [Full Text] [Related]
15. Frequent expression of CD45RO memory T cell marker as well as low to high expression of pd-1 and PD-L1 inhibitory molecules in seminoma and dysgerminoma.
Farahani H; Dehghanian AR; Khademolhosseini A; Haghshenas MR; Erfani N
J Reprod Immunol; 2024 Feb; 161():104184. PubMed ID: 38171036
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer.
Chen S; Li X; Ao W
BMC Womens Health; 2024 Jan; 24(1):6. PubMed ID: 38166898
[TBL] [Abstract] [Full Text] [Related]
17. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract] [Full Text] [Related]
18. pd-1 and TIGIT coexpressing CD8 + CD103 + tissue-resident memory cells in endometrial cancer as potential targets for immunotherapy.
Jiang F; Mao M; Jiang S; Jiao Y; Cao D; Xiang Y
Int Immunopharmacol; 2024 Jan; 127():111381. PubMed ID: 38150880
[TBL] [Abstract] [Full Text] [Related]
19. PD-L1 and pd-1 Expression in Early Stage Uterine Endometrioid Carcinoma.
An HJ; Yang JW; Kim MH; Song DH
In Vivo; 2024; 38(1):246-252. PubMed ID: 38148043
[TBL] [Abstract] [Full Text] [Related]
20. Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8
Luan X; Lei T; Fang J; Liu X; Fu H; Li Y; Chu W; Jiang P; Tong C; Qi H; Fu Y
Mol Ther; 2024 Feb; 32(2):469-489. PubMed ID: 38098230
[TBL] [Abstract] [Full Text] [Related]
[Next]
